Novartis, which bought the biotech firm in 2018, announced that the company’s top scientists have left, and news reports say it’s because they were involved in using manipulated data to get the gene therapy Zolgensma approved.
A trial is recruiting patients to test the gene-editing technology’s ability to treat an inherited form of blindness caused by a mutation in the CEP290 gene.
Two clinical trials that altered vasopressin signaling report improved social functions in people with autism spectrum disorder, but researchers caution against overinterpreting the results.
Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.
Breast cancer researcher and oncologist Nancy Davidson discusses what we’ve learned from the first wave of epigenetic trials for breast cancer, and what challenges lie ahead before such therapies reach the clinic.
Most people who contracted the disease were unvaccinated and some state legislatures are now considering whether to curtail nonmedical vaccine exemptions.
Plasmodium falciparum has shown an ability to evade everything we throw at it, most recently artemisinin-based combination therapies, today’s front-line treatment.
The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.
Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.